These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 22768329)

  • 21. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.
    Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
    Metabolism; 2012 Jun; 61(6):823-35. PubMed ID: 22209663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In obese mice, exercise training increases 11β-HSD1 expression, contributing to glucocorticoid activation and suppression of pulmonary inflammation.
    Du SF; Yu Q; Chuan K; Ye CL; He ZJ; Liu SJ; Zhu XY; Liu YJ
    J Appl Physiol (1985); 2017 Oct; 123(4):717-727. PubMed ID: 28663379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
    Prasad Sakamuri SS; Sukapaka M; Prathipati VK; Nemani H; Putcha UK; Pothana S; Koppala SR; Ponday LR; Acharya V; Veetill GN; Ayyalasomayajula V
    PLoS One; 2012; 7(12):e50216. PubMed ID: 23284633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
    Hong SP; Han D; Chang KH; Ahn SK
    Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
    Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
    Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
    Alberts P; Engblom L; Edling N; Forsgren M; Klingström G; Larsson C; Rönquist-Nii Y; Ohman B; Abrahmsén L
    Diabetologia; 2002 Nov; 45(11):1528-32. PubMed ID: 12436336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
    Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
    Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization.
    Nixon M; Wake DJ; Livingstone DE; Stimson RH; Esteves CL; Seckl JR; Chapman KE; Andrew R; Walker BR
    Diabetes; 2012 Apr; 61(4):790-6. PubMed ID: 22357964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
    Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
    J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
    Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
    Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice.
    Wamil M; Battle JH; Turban S; Kipari T; Seguret D; de Sousa Peixoto R; Nelson YB; Nowakowska D; Ferenbach D; Ramage L; Chapman KE; Hughes J; Dunbar DR; Seckl JR; Morton NM
    Diabetes; 2011 Apr; 60(4):1158-67. PubMed ID: 21350084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis.
    Kipari T; Hadoke PW; Iqbal J; Man TY; Miller E; Coutinho AE; Zhang Z; Sullivan KM; Mitic T; Livingstone DE; Schrecker C; Samuel K; White CI; Bouhlel MA; Chinetti-Gbaguidi G; Staels B; Andrew R; Walker BR; Savill JS; Chapman KE; Seckl JR
    FASEB J; 2013 Apr; 27(4):1519-31. PubMed ID: 23303209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice.
    Wang YJ; Huang SL; Feng Y; Ning MM; Leng Y
    Acta Pharmacol Sin; 2012 Sep; 33(9):1195-203. PubMed ID: 22922341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute anti-obesity effects of intracerebroventricular 11β-HSD1 inhibitor administration in diet-induced obese mice.
    Seo M; Islam SA; Moon SS
    J Neuroendocrinol; 2018 Mar; 30(3):e12580. PubMed ID: 29418022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages--role of 11beta-HSD1 in pro-inflammatory properties in macrophages.
    Ishii T; Masuzaki H; Tanaka T; Arai N; Yasue S; Kobayashi N; Tomita T; Noguchi M; Fujikura J; Ebihara K; Hosoda K; Nakao K
    FEBS Lett; 2007 Feb; 581(3):349-54. PubMed ID: 17239856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of 11β-HSD1 expression during adipose tissue expansion by hypoxia through different activities of NF-κB and HIF-1α.
    Lee JH; Gao Z; Ye J
    Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1035-41. PubMed ID: 23512810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.